Cargando…

Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review

Anticholinergics have been used in the treatment of overactive bladder (OAB), but their use is limited by poor tolerability and anticholinergic-related side effects. Increasingly, providers are discontinuing anticholinergic prescribing because of growing evidence of the association of anticholinergi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dmochowski, Roger R., Newman, Diane K., Rovner, Eric S., Zillioux, Jacqueline, Malik, Rena D., Ackerman, A. Lenore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567877/ https://www.ncbi.nlm.nih.gov/pubmed/37725308 http://dx.doi.org/10.1007/s12325-023-02625-8

Ejemplares similares

Effect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder
por: Han, Young Kook, et al.
Publicado: (2011)

Refractory overactive bladder: Beyond oral anticholinergic therapy
por: Glinski, Ronald W., et al.
Publicado: (2007)

Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder
por: Araklitis, George, et al.
Publicado: (2020)

Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder
por: Dmochowski, Roger R., et al.
Publicado: (2023)

Third‐line therapy for overactive bladder in the elderly: Nuances and considerations
por: Zillioux, Jacqueline, et al.
Publicado: (2022)

The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive Bladder
por: Dmochowski, Roger, et al.
Publicado: (2023)

Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions
por: Rutman, Matthew P., et al.
Publicado: (2021)

The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder
por: Gurocak, Serhat, et al.
Publicado: (2015)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
por: Sartori, Luisa Gracio Ferreira, et al.
Publicado: (2023)

Update on the management of overactive bladder: patient considerations and adherence
por: Gomelsky, Alex, et al.
Publicado: (2010)

Anticholinergic Burden and Associated Healthcare Resource Utilization in Older Adults with Overactive Bladder
por: Jaggi, Ashley, et al.
Publicado: (2021)

Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics
por: Yehoshua, Alon, et al.
Publicado: (2016)

Clinical Efficacy in the Treatment of Overactive Bladder Refractory to Anticholinergics by Posterior Tibial Nerve Stimulation
por: Arrabal-Polo, Miguel Angel, et al.
Publicado: (2012)

Efficacy and Tolerability of Anticholinergics in Korean Children with Overactive Bladder: A Multicenter Retrospective Study
por: Park, Se Jin, et al.
Publicado: (2014)

Initial clinical experience with selective bladder denervation for refractory overactive bladder
por: Tu, Le Mai, et al.
Publicado: (2018)

Erratum: Efficacy and Tolerability of Anticholinergics in Korean Children with Overactive Bladder: A Multicenter Retrospective Study
por: Park, Se Jin, et al.
Publicado: (2015)

Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder
por: Lozano-Ortega, Greta, et al.
Publicado: (2020)

The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents
por: Masumori, Naoya, et al.
Publicado: (2011)

Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports
por: Shiota, Takako, et al.
Publicado: (2014)

Rationale for the Use of Anticholinergic Agents in Overactive Bladder With Regard to Central Nervous System and Cardiovascular System Side Effects
por: Çetinel, Bülent, et al.
Publicado: (2013)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

The Impact of Anticholinergic Use for Overactive Bladder on Cognitive Changes in Adults with Normal Cognition, Mild Cognitive Impairment, or Dementia
por: Welk, Blayne, et al.
Publicado: (2022)

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
por: Sievert, K-D, et al.
Publicado: (2014)

Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2014)

Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study
por: Szabo, Shelagh M, et al.
Publicado: (2019)

Prevalence and Factors Associated with Cumulative Anticholinergic Burden Among Older Long-Stay Nursing Home Residents with Overactive Bladder
por: Chatterjee, Satabdi, et al.
Publicado: (2021)

The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US
por: Chatterjee, Satabdi, et al.
Publicado: (2021)

Use of overactive bladder anticholinergic medications associated with falls leading to emergency department visits: results from the ADRED study
por: Just, Katja S., et al.
Publicado: (2023)

Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: A systematic review and meta-analysis
por: Yi, Wei, et al.
Publicado: (2021)

A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA
por: Campbell, Noll L., et al.
Publicado: (2021)

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis
por: Kennelly, Michael, et al.
Publicado: (2022)

Gene Therapy for Overactive Bladder: A Review of BK-Channel α-Subunit Gene Transfer
por: Andersson, Karl-Erik, et al.
Publicado: (2021)

Assessment of Anticholinergic Use After Fading of BTX-A Effects in Refractory Idiopathic Overactive Bladder: A Prospective Blinded Randomized Trial
por: Elbaset, M.A., et al.
Publicado: (2019)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence
por: Campbell, Jonathan D, et al.
Publicado: (2009)

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
por: Carlson, Kevin V., et al.
Publicado: (2021)

Knowledge and attitude for overactive bladder care among women: development and measurement
por: Chhatre, Sumedha, et al.
Publicado: (2018)

Exploring Concomitant Acetylcholinesterase Inhibitor and Overactive Bladder Anticholinergic Use and Risk of Hospitalization in Medicare and Dual-Eligible Medicare–Medicaid Populations in a Historic Database
por: Watanabe, Jonathan H., et al.
Publicado: (2023)

Postmenopausal overactive bladder
por: Tomaszewski, Jacek
Publicado: (2014)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0n77ass1qj6t988rcfsp8hr3us